Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Fonar Corporation (FONR) Stock Forecast & Price Prediction United States | NASDAQ | Healthcare | Diagnostics & Research
$14.78
+0.53 (3.72%)Did FONR Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if FONAR is one of their latest high-conviction picks.
FONR has shown a year-to-date change of -2.4% and a 1-year change of -5.0%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for FONR. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for FONR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
The following stocks are similar to FONAR based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Fonar Corporation has a market capitalization of $89.72M with a P/E ratio of 12.8x. The company generates $105.43M in trailing twelve-month revenue with a 7.1% profit margin.
Revenue growth is +4.3% quarter-over-quarter, while maintaining an operating margin of +12.3% and return on equity of +5.8%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Develops and manufactures MRI scanners and equipment.
Fonar Corporation generates revenue by designing and producing advanced MRI scanners and imaging equipment, which are sold to hospitals, diagnostic centers, and medical practices. Their unique multi-position imaging technology enhances diagnostic accuracy, making their products essential in modern healthcare.
Founded in 1978, Fonar was the first company to create an MRI scanner, establishing a strong legacy in medical diagnostics. Headquartered in Melville, New York, the company is committed to ongoing research and development to drive innovation in the healthcare sector.
Healthcare
Diagnostics & Research
535
Mr. Timothy R. Damadian M.D.
United States
1993
FONR reports top-line growth in Q1 fiscal 2026, despite a decline in earnings and an increase in SG&A and operating expenses.
FONR's revenue growth amidst declining earnings and rising costs signals potential profitability challenges, impacting future performance and investor sentiment.
As of September 30, 2025, cash and cash equivalents decreased 4% to $54.3 million, while total net revenues rose 4% to $26.0 million year-over-year.
The decline in cash and cash equivalents may indicate liquidity concerns, while the revenue growth suggests potential operational improvement, impacting overall financial stability and future valuation.
FONR reported increased costs and decreased profits for fiscal 2025, despite growth in scan volumes and imaging service revenues.
Higher costs and lower profits for FONR signal potential challenges in profitability, which may affect stock performance and investor sentiment despite revenue growth.
As of June 30, 2025, cash and cash equivalents remained stable at $56.3 million. Total net revenues increased 1% to $104.4 million year-over-year.
Stable cash reserves and slight revenue growth indicate financial stability, suggesting the company can weather economic fluctuations and invest in future opportunities.
FONR utilizes hybrid MRI technology and maintains a robust balance sheet to address industry challenges, while facing rising costs and regulatory risks in claim collections.
FONR's hybrid MRI tech and solid balance sheet position it well amid industry challenges, but rising costs and regulatory risks could impact profitability and cash flow.
FONAR Corporation's Board received a proposal from a group led by Timothy Damadian to acquire all outstanding shares for $17.25 each in cash.
FONAR's potential acquisition at $17.25 per share indicates a premium, which could impact stock valuation, investor sentiment, and trading strategies.
Analyst forecasts for Fonar Corporation (FONR) are not currently available. The stock is trading at $14.78.
Analyst ratings for FONR are not currently available. The stock is currently trading at $14.78. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
Price predictions from Wall Street analysts for FONR are not currently available. The stock is trading at $14.78.
Fonar Corporation generates revenue by designing and producing advanced MRI scanners and imaging equipment, which are sold to hospitals, diagnostic centers, and medical practices. Their unique multi-position imaging technology enhances diagnostic accuracy, making their products essential in modern healthcare.
Price targets from Wall Street analysts for FONR are not currently available. The stock is trading at $14.78.
Price targets from Wall Street analysts for FONR are not currently available. The stock is trading at $14.78.
Analyst ratings for FONR are not currently available. The stock is trading at $14.78.
Stock price projections, including those for Fonar Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.